Investor Relations
Press Releases
Events & Webcasts
Presentations & Publications
Corporate Governance
Financial Information
Stock Information
Contact Us
Shareholder Tools
Shareholder Briefcase
Printed Materials
Email Alerts
Download Library
RSS News Feeds
Search Investor Relations
Investor site
Section only
Print page
Email page
Presentations & Publications
Year:
All Years
2010
Title
Date
Type
Size
Hana Biosciences Corporate Presentation
06/16/2010
2.1 MB
Publications
Year:
All Years
2009
2007
2006
Title
Date
Type
Size
A Phase 2 Study of Marqibo® in Adult Patients with Ph- ALL in Second Relapse or Who Progressed Following Two Treatment Lines
12/07/2009
108.6 KB
A Pivotal Study of Marqibo in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Second Relapse: Preliminary Results of an Interim Analysis of the rALLy Study
06/02/2009
129.2 KB
A Phase 2 Study of Marqibo in Patients with Metastatic Uveal Melanoma
06/02/2009
83.1 KB
Safety and Efficacy of Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) for the Treatment of Adults with Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)
12/08/2007
88.9 KB
Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) Concentrates Vincristine in Tumor Tissue and Lymphoid Malignancy Oriented Tissues in Tumor-Bearing Mice
12/08/2007
217.4 KB
Vincristine Sulfate Liposomes Injection Concentrates Vincristine in Tumor Tissue and Bone marrow of Tumor-Bearing Mice
10/25/2007
102.9 KB
Vinorelbine Liposomes Injection results in Greater Tumor Drug Exposure Compared to Conventional Vinorelbine in Tumor-Bearing Nude Mice
10/25/2007
92.6 KB
A Pharmacokinetic Study of a Novel Sphingomyelin/Cholesterol Liposomal Topotecan and Non-Liposomal Topotecan in Rats
10/25/2007
103.3 KB
A Phase 1 and Pharmacokinetic (PK) Profile Study of Vinorelbine Liposomes Injection in Patients with Advanced Solid Tumors, Non-Hodgkin's Lymphoma, and Hodgkin's Disease
10/23/2007
62.6 KB
A pharmacokinetic comparison of the Marqibo® 3- and 5-vial injection kits in metastatic melanoma patients
06/03/2007
141.3 KB
Steroids and immunosuppressive agents potentiate the cytotoxicity of the EGFR inhibitor erlotinib (E) in human skin keratinocytes whereas menadione (Vit K3) exerts a protective effect: implications for the management of the skin rash
06/02/2007
618.1 KB
Topical Vitamin K3 (Menadione) Prevents Erlotinib and Cetuximab-Induced EGFR Inhibition in the Skin
06/04/2006
195.3 KB
= add file to Briefcase
© 2010 Hana Biosciences.
Web design by Global 1 Design.
